MedTrace Logo

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04271514 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2021-09-30

No results posted yet for this study

Summary

This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.

Conditions

Interventions

DRUG

RPT193

Antagonist of the CCR4 chemokine receptor

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • RAPT Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Laurence Cheng, MD, PhD · RAPT Therepeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-12
Primary Completion
2021-04-26
Completion
2021-04-26
FDA Drug
Yes

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04271514 on ClinicalTrials.gov